Galapagos’ Board of Directors has appointed Dr. Mummery to fill the vacancy that has arisen on His most recent roles at Goldman Sachs were as part of the European Special Situations and Principal Strategies teams where he established and led the private healthcare investing effort. He attended undergraduate school at Vanderbilt University and graduate school at Emory University (GA) in geology. In 2002, she became a Professor at the Utrecht University Medical Centre in the Netherlands. Before joining Goldman Sachs, he was a corporate lawyer with the law firm Sullivan & Cromwell LLP. In addition, he founded Futerra Fuels International, a company focused on sustainable energy generation through the conversion of biomass to biocoal. Mr. Rowe is Managing Director at Hayfin Capital Management LLP. Mary Kerr, Ph.D., has served as a member of our board of directors since 26 July 2016. Previously she served as Grassroots Director for the Chesapeake Bay Foundation, coordinating all the CBF’s citizen involvement and as Assistant State Naturalist for the State of Vermont. Show your support and help us fund vital conservation efforts to protect endangered species in Galapagos. She served on the Ethical Councils of the Dutch Ministry of Health, is member of the Royal Netherlands Academy of Arts and Sciences (KNAW), the KHMW, editor of the Cell Press journal Stem Cell Reports, (vice) president of the International Society for Stem Cell Research and past-president of the International Society of Differentiation. Each board member provided feedback through individual assessment forms. The Chairman is a non-executive director and does not hold the office of CEO. Galapagos' Board of Directors has appointed Dr. Mummery to fill the vacancy that has arisen on the Board as a result of the resignation of Dr. Vicky Sato on 31 December 2014. A dedicated conservationist, she has been a founding member and Board member of various international conservation organizations, including Fundación Natura where she was the president of the board of directors. Before joining Abt Associates, Dr. San Martin was Partner in charge of PricewaterhouseCoopers’ (PwC) International Financing Institutions (IFI) practice. He received his MA in Biochemistry and DPhil in Molecular Medicine from the University of Oxford, where he has also been a Senior Research Fellow and Professor. *In 2010, Galapagos Conservancy’s Board of Directors approved a change in the organization’s fiscal year from January 1 – December 31 to April 1 – March 31. Within the scope of the authorized capital, the Board of Directors can issue shares with or without voting rights. Dr. Kerr was a founding member and on the Corporate Executive team of ViiV Healthcare where she led a turnaround in the performance of the HIV business in Europe. He lives in Cincinnati, Ohio. “We are pleased to welcome Ronald back to our Board of Directors,” said Onno van de Stolpe, CEO of Galapagos. He was the President of the Belgian-Luxemburg Chamber of Commerce for Russia and Belarus until June 2010. She has spent the majority of her career on the R&D commercial interface in global strategy and regional operational roles, predominantly in the specialty and orphan space. Photo © Jessica Haverstick. Galapagos Conservancy, Inc.® is a registered 501(c)(3) non-profit organization with EIN Tax ID # 13-3281486. Mechelen, Belgium; 1 April 2011 - Galapagos NV (Euronext: GLPG) announced today that it will propose the appointment of Dr Vicki Sato to its Board of Directors at its Annual General Shareholders' Meeting on 26 April 2011. Galapagos NV’s board of directors consists of minimum five and maximum nine members, including the Chairman and the CEO. He has served on numerous not-for-profit and corporate board boards of private companies in the Caribbean Basin and broader Latin America, where he travels extensively on an ongoing basis. She was a postdoctoral fellow from 1981 to 1984 at the Hubrecht Institute in Utrecht, where she later also served as a staff scientist and group leader until 2008. Ms. Swanson joined the Board in 2018. This change to the calendar-year reporting cycle began on January 1, 2011 resulting in a short, 3-month FY11. October 1, 2020. Dr. Parekh is a General Partner at Advent Life Sciences LLP, which he joined in 2006. He became a Galapagos guide in 1985 and has been working in the Islands as chief naturalist for International Nature and Culture Adventures (INCA) since 1990. The results were presented on an aggregate basis by the secretary of the board and served as a basis for discussion by the full board. MECHELEN, BELGIUM--(Marketwire - April 01, 2011) - Galapagos NV (Euronext: GLPG) announced today that it will propose the appointment of Dr Vicki Sato to its Board of Directors at its Annual General Shareholders' Meeting on 26 April 2011. In 2015, Galapagos signed a collaboration agreement with Gilead for the development and commercialization of filgotinib. She was also Executive President of the Quito Zoo. Mr. Polatty joined the Board in 2016. Dr. Cautreels, who had previously served as an independent director, no longer met the independence criteria upon his reappointment for a fourth consecutive term on 24 April 2018 because article 526ter, 2° of the Belgian Companies Code only allows for a maximum of three consecutive terms for independent directors. Lori played a large role in helping the organization establish a solid digital presence though its website, email communications, and online engagement, while staying current through rapidly changing online trends over the … Dr. Sherman lives in Lafayette, California. Ms. Bosley served as the President, Chief Executive Officer and member of the board of directors of Editas Medicine, Inc. from June 2014 to March 2019. The attendance rate for the other meetings was as follows: Dr. Parekh: 67%; Mr. Van de Stolpe: 92%; Dr. Cautreels: 100%; Dr. Van Barlingen: 100%; Mr. Rowe: 83%; Ms. Bosley: 75%; Dr. Mummery: 92% and Dr. Kerr: 92%. We are pleased to announce that Bob Rajan has joined the board of directors of Galapagos Holding S.A. as an additional independent non-executive director, effective as … The Board of Directors of Galapagos Conservancy, Inc. (“Galapagos Conservancy” or “GC”) announces the appointment of Dr. Paul Salaman as President of GC following the retirement of its former President and founder, Johannah Barry. Dr. Charles Lane, Secretary. The overall attendance rate was 88%. Galapagos Conservancy is led by a volunteer Board of Directors who bring a wide variety of expertise and enthusiasm to GC. During an academic career at Oxford University, he co-founded Oxford GlycoSciences PLC, where he served as Chief Scientific Officer and Chief Executive Officer from 1988 until its sale to Celltech Group PLC (now UCB SA) in 2003. He received his undergraduate degree from Dartmouth and his MBA and JD degrees from the University of Virginia. Dr. Charles Knapp joined the Board in 2020. He has founded or served on the boards of several life sciences companies in the United States and Europe including Celldex Therapeutics, Inc.; Avila Therapeutics, Inc.; EUSA Pharma (Europe) Limited; Thiakis Limited; Biocartis NV; Amsterdam Molecular Therapeutics (AMT) Holding NV (now uniQure); Aura, Inc.; Itara Ltd.; and Cellnovo SA. Onno van de Stolpe – Please refer to the “Composition of Galapagos NV’s executive committee” for a biography. Dr. Charles Knapp. Using iguanas as model organisms, his research focuses primarily on understanding the effects of anthropogenic disturbance on endangered taxa and designing conservation strategies to prevent further population declines and habitat degradation. On behalf of the board of directors, Onno van de Stolpe CEO Raj Parekh Chairman of the board of directors THE GALAPAGOS GROUP 10 Galapagos NV • H1 Report 2019 Our privacy statement explains how we use cookies, and how to change your cookie settings. In proposing candidates, particular consideration is given to diversity in gender, age, nationality, educational and professional background, as well as complementary skills, knowledge and experience. Galapagos NV’s board of directors consists As of 2008, Dr. Christine Mummery is Professor of Developmental Biology and Chair of the Department of Anatomy and Embryology at the Leiden University Medical Centre (LUMC) in … He is also active in conservation programs on mainland Ecuador. Dr. Lane’s published research areas and expertise include systems and aquatic ecology, watershed hydrology, biogeochemistry, remote sensing, and geospatial analyses. In addition, she chairs the executive board of the Institute for human Organ and Disease Model Technologies (hDMT), a non-profit R&D institute of which the LUMC is a founding partner. He received his Bachelor of Science degree in Zoology (1991) from Southern Illinois University, and his Master of Science (1999) and Ph.D. (2005) in Wildlife Ecology and Conservation from the University of Florida. Ms. Bosley graduated from Cornell University with a B.A. She served as President, Celgene Avilomics Research at Celgene in 2012. Donations are tax-deductible to the extent allowed by law in your country. Warrant Plan 2010 (C), 23 December 2010, p. 2/4 The renewed power of attorney regarding the authorized capital is valid for a period of five years as of 2 June 2009. jldebakey@galapagos.org Director of Operations Melissa Combs mc@galapagos.org Membership Services Coordinator Diana Fulchiron dfulchiron@galapagos.org Galapagos Ambassadors Manager Alyson Wells awalty@galapagos.org Foundation Development Manager/ Office Manager Kelly Wilmeth kjones@galapagos.org Board of Directors Chairman Dr. David … Kicker Rock from Cerro Brujo, San Cristóbal. Ms Bosley was appointed to... | April 3, 2021 Dr. A 20-year programming executive spanning leadership roles at broadcast and major cable networks, Campbell served as President of Discovery Networks US following his role as President of Miramax Television, where he led the production of Emmy-nominated “Project Greenlight.” A native of Greenville, SC, Campbell is a 1982 graduate of Harvard College and a 1987 graduate of the Harvard Business School (MBA). A formal evaluation of the board and its committees was initiated in December 2017 and was completed in March 2018. Thank you, Elizabeth, and welcome, everybody, to this webcast. He is Senior Research Scientist with the US federal government who has been leading and conducting ecological research for over 15 years. As of 2008, Dr. Christine Mummery is Professor of Developmental Biology and Chair of the Department of Anatomy and Embryology at the Leiden University Medical Centre (LUMC) in … 04.06.21 April 6, 2021 This month, the largest and most-utilized evaluator of charities,... More >, 03.29.21 March 28, 2021 On the afternoon of Sunday, March 28, Galapagos National Park... More >, 03.02.21 March 2, 2021 On Friday, February 26, 191 juvenile tortoises of the Chelonoidis... More >, By Wacho Tapia, Director of the Giant Tortoise Restoration Initiative Alcedo... More >, By Lucas Bustamante, co-founder at Tropical Herping and Giant Tortoise Restoration... More >, By Linda Cayot, retired GC Science Advisor In July 2012 a mere two weeks... More >. he was Medical Director for Zambon BV. During 2018, Galapagos NV complied with the Law of 28 July 2011 with respect to gender diversification in the board of directors, and the board will continue to monitor future compliance. Dr Vicki Sato to be appointed to Galapagos ’ Board of Directors . Galapagos NV’s board of directors consists Ms. Bosley joined Adnexus Therapeutics from Biogen Idec, Inc. where she had roles in business development, commercial operations and portfolio strategy in the United States and Europe. He is Vice President of Conservation Research at Shedd Aquarium and has been conducting research in the wider Caribbean for 25 years. MECHELEN, BELGIUM -- (Marketwire) -- 04/01/11 -- Galapagos NV (Euronext: GLPG) announced today that it will propose the appointment of Dr Vicki Sato to its Board of Directors at its Annual General Shareholders' Meeting on 26 April 2011.Dr Sato was President of Vertex Pharmaceuticals from 2000 to 2005, where she led research and development, business and … Dr. Brus was already a member of the Galapagos Board of Directors from 2000 until Galapagos’ IPO in May 2005. Each of the directors’ expertise and experience is exemplified by the varied professional activities they carry out and offices they hold. In 2019, Galapagos entered into a transformative 10-year global research and development collaboration with Gilead. Other endeavors have included working in the Antarctic since 1990 as expedition leader on various vessels and since the early 1990s he has been a research associate of Oceanites, which runs the Antarctic Site Inventory. We use cookies to help us improve your browsing experience and understand how people use our website. Mr. Polatty lives on the island of Santa Cruz, Galapagos and Tumbaco, Ecuador. Rajesh Parekh, MA, DPhil has served as the Chairman of our board of directors since 2004. He also was a Conservation Research Postdoctoral Fellow (2010) with the Institute for Conservation Research at the San Diego Zoo. Furthermore, our board members have different educational backgrounds, as can be read in each of their profiles (above). Galapagos Announces Changes to Board of Directors Tuesday May 24, 2:06 am ET MECHELEN, Belgium, May 24, 2005 (PRIMEZONE) -- Galapagos NV, a genomics-based drug discovery company, announces changes to its Board of Directors. Galapagos NV, Board of Directors, Special Report (Article 583 BCC), Warrant Plan 2010, 26 March 2010 P. 5/10 1. He graduated from the University of Antwerp, with a Doctorate in Chemistry, specializing in mass spectrometry. He lives in southern Virginia. Campbell has served on the boards of Cricket Media, a leading education infrastructure company, The National Parks Conservation Association, The Jane Goodall Institute, and currently is on the board of the KentWool Corporation. BASE AND PURPOSE The Board of Directors of GALAPAGOS NV (hereinafter referred to as “the Company”) has approved the present Warrant Plan 2010 by resolution of 26 March 2010 (and notary deed of 27 April 2010). in Physics, Electronics, and Mathematics at the University of Nottingham and her Ph.D. in BioPhysics at London University in the United Kingdom. Mechelen, Belgium; 1 April 2011 – Galapagos NV (Euronext: GLPG) announced today that it will propose the appointment of Dr Vicki Sato to its Board of Directors at its Annual General Shareholders’ Meeting on 26 April 2011. Critical accounting estimates and judgments, 14. Prior to her time at Avila Therapeutics she was Vice President, Strategic Operations at Adnexus, a Bristol-Myers Squibb R&D Company, and was Vice President, Business Development at Adnexus Therapeutics, Inc. before that. Mechelen, Belgium; 4 March 2013 - Galapagos NV announced today the appointment of Katrine Bosley to its Board of Directors as an independent Non-Executive Director. From 2009 to 2012, she was President, Chief Executive Officer and member of the board of directors of Avila Therapeutics, Inc., which was acquired by Celgene Corporation in 2012. As Director of the Botanical Gardens, she rebuilt and opened to the public the first Botanical garden in the city of Quito and created it as a primary reference facility for ex-situ conservation of plants. Prior to joining Solvay he was employed by Sanofi SA, Sterling Winthrop, Inc. and Nycomed Amersham PLC in a variety of R&D management positions in Europe and in the United States from 1979 to 1998. Mr. Bradley T. Johnson, Chair. She currently serves on the boards of Genocea Biosciences, Inc., the Biotechnology Innovation Organization and of the Massachusetts Eye and Ear Institute. The board of directors acts as a collegial body. Ms. Swanson lives in Annapolis, Maryland. In 2018, the board of directors held four regular meetings, eight meetings by telephone conference to discuss specific matters and two meetings in the presence of a notary (relating to the issuance of Warrant Plan 2018 and Warrant Plan 2018 RMV, and the issuance of shares with cancellation of the shareholders’ preferential subscription rights). in Biology. She is further on the scientific advisory boards of the Gurdon Institute (Cambridge, UK), Stem Cell Australia and the Allen Institute, Seattle. The nomination and remuneration committee nominates, for the approval of the board, candidates to fill vacancies and advises on proposals for appointment originating from shareholders, in each case taking into account Galapagos’ needs and the selection criteria determined by the board. Trade and other receivables and other current assets, “Composition of Galapagos NV’s executive committee”, Remuneration of non-executive directors of Galapagos NV, Remuneration of executive directors of Galapagos NV, nexxar - digital reporting evolved - Online Report. Prior to joining Plan, Dr. San Martin was Group Vice President for Abt Associates, overseeing all the technical assistance, policy research and strategic business consulting provided by Abt Associates to its clients overseas. He holds a medical degree from the University of Groningen. He has worked extensively in Latin America, Europe, Africa and Asia, and has lived in Latin America, Europe and the Caribbean. In 2018, the board thus consisted of three women and five men (as from 24 April 2018: four men), representing four different nationalities and different age categories. He is now in private practice specializing in cross border transactions and new business development. This evaluation specifically addressed the functioning of the board, the size and composition of the board, the interaction between the board and the executive management, and the functioning of the audit committee and the nomination and remuneration committee. Mr. Rowe received his Bachelor of Science in Psychobiology from the University of Southern California and his JD from Harvard Law School. Mechelen, Belgium; 1 April 2011 - Galapagos NV (Euronext: GLPG) announced today that it will propose the appointment of Dr Vicki Sato to its Board of Directors … While living in Washington, DC he served on the Board of Trustees for the National Symphony Orchestra and the Imagination Stage. When a position on the board becomes vacant, the other directors may temporarily fill the mandate until the shareholders’ meeting appoints a new director. She is President and CEO of Plan International USA, one of the oldest and largest international development organizations in the world with offices in 51 countries across Africa, Asia, and the Americas. He currently serves as a member of the Board of Managers of Paradigm Spine LLC. Galapagos announces that Dr. Mary Kerr has been nominated to join the Board of Directors of Galapagos, subject to shareholder approval during the Special Shareholders` Meeting on 26 July 2016. Mr. Lea holds a Bachelor of Science in Finance, Management and Meteorology from the University of North Carolina at Asheville and currently resides in Curaçao in the Dutch Antilles. Dr. Kerr, a UK national, is Chief Executive Officer and director at NeRRe Therapeutics and Chief Executive Officer and director at KaNDy Therapeutics. Ms. Carolina Jijon is the director of the Quito Botanical Gardens, a position she has held since 2004 and she concurrently holds the position of Executive Director of the Botanical Foundation of the Andes. Galapagos NV (Euronext&NASDAQ: GLPG) announced the appointment of Dr. Christine Mummery to its Board of Directors as an independent non-executive director. Lori Ulrich joined Galapagos Conservancy in 2006 with a role in communications, then production, and is now the Director of Membership and Marketing. In view of Galapagos' listing on Euronext Amsterdam and Euronext Brussels, Galapagos' Board has changed in composition. Dr. Kerr gained a Ph.D. in Pharmacology at the University of Bradford, did post-doctoral research at the Michigan Cancer Foundation in Detroit and has an MBA from the University of Kingston. Mary Kerr, Ph.D. - Non-Executive Independent Director. The board’s role is to pursue the long-term success of Galapagos. He is a co-founder and board member of Accoy Pharmaceuticals since 2016. Dr. Paul Salaman poses with a land iguana in Galapagos. During its meetings in 2018, the board dealt with matters pertaining to, among other things, our strategy and growth, the evaluation of business development opportunities, convening of the shareholders' meeting and preparation of resolutions to be submitted for approval to the shareholders, review and approval of our financial reporting and assessment of the board and its committees. Dr. Mette joined the Board in 2016. Prior to her appointment at NeRRe, Dr. Kerr held a range of senior leadership roles at GSK over more than 20 years, most recently as Senior Vice President and Global Franchise leader for the Immuno-inflammation and Infectious Diseases franchise. She has also held senior positions in the World Bank Group. 11150 Fairfax Boulevard, Suite 408 Fairfax, VA 22030, US, Repopulating Islands Where Tortoises Went Extinct, Human-Tortoise Interactions, Conflicts, and Mitigations, Establishing a Demonstration School and Training Center, Future Leaders: Building Capacity for a Sustainable Galapagos, Landbird Conservation & Control of 'Philornis downsi', Introduced Species: Quarantine and Control, Strategic Planning for the Tomás de Berlanga School, Galapagos Conservancy Awarded Top Rating for Efficiency, Accountability, and Transparency, BREAKING: 185 Baby Galapagos Tortoises Seized from Illegal Traffickers, Final Phase of the Santa Fe Tortoise Repopulation Process Complete, Rediscovering the Giant Tortoises and Magical Landscapes of Alcedo Volcano, Documenting Galapagos Giant Tortoises: Walking Among Modern Dinosaurs, ‘Galapagos Giant Tortoises:’ Synthesis of a Half Century of Study and Conservation. Galapagos' Board of Directors has appointed Dr. Mummery to fill the vacancy In 2018, the following persons were members of the board: Dr. Parekh (Chairman), Mr. Van de Stolpe (CEO), Dr. Van Barlingen (until 24 April 2018), Dr. Cautreels, Mr. Rowe, Ms. Bosley, Dr. Mummery and Dr. Kerr; the latter four directors were appointed as independent directors within the meaning of article 526ter of the Belgian Companies Code. Mr. Johnson joined the Board in 2014. Ms. Jijon is a graduate of the Catholic University of Quito with a Bachelor’s degree in Biology and is a published author on the subject of conservation management.
Seronegative Sjögren's Syndrome Symptoms, Peterborough Fc Trials, King's College Covid Vaccine, Celeste In The City Streaming, Ta Instruments Dsc Software, Rent My Cargo Van, What Is Kill Switch, Blackhawks Logo Redesign, Fcl Share Price History, Preloved Cats Liverpool,